GETINGE AB/ADR (OTCMKTS:GNGBY) versus Viewray (OTCMKTS:VRAY) Head-To-Head Analysis

GETINGE AB/ADR (OTCMKTS:GNGBY) and Viewray (NASDAQ:VRAY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Dividends

GETINGE AB/ADR pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Viewray does not pay a dividend.

Profitability

This table compares GETINGE AB/ADR and Viewray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GETINGE AB/ADR -2.41% 8.50% 3.81%
Viewray -128.13% -67.02% -35.25%

Risk & Volatility

GETINGE AB/ADR has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Viewray has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for GETINGE AB/ADR and Viewray, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GETINGE AB/ADR 0 0 0 0 N/A
Viewray 0 1 8 0 2.89

Viewray has a consensus target price of $8.56, indicating a potential upside of 221.64%. Given Viewray’s higher possible upside, analysts plainly believe Viewray is more favorable than GETINGE AB/ADR.

Earnings and Valuation

This table compares GETINGE AB/ADR and Viewray’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GETINGE AB/ADR $2.67 billion 1.41 -$111.30 million N/A N/A
Viewray $80.96 million 3.24 -$76.40 million ($0.98) -2.71

Viewray has lower revenue, but higher earnings than GETINGE AB/ADR.

Institutional & Insider Ownership

0.0% of GETINGE AB/ADR shares are held by institutional investors. 15.5% of Viewray shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GETINGE AB/ADR beats Viewray on 8 of the 13 factors compared between the two stocks.

About GETINGE AB/ADR

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Surgical Workflows, and Life Science segments. It offers practice-oriented monitoring systems and disposables; anesthesia, beating heart surgery, and ceiling devices; washer-disinfectors, consumables, and IT-solutions; connected solutions; consumables products; drain products; endoscope reprocessing; endoscopic vessel harvesting systems; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packaging services; intra-aortic balloon counter pulsation therapies; critical care ventilators; modular room systems; operating lights; operating tables and accessories; operating room (OR) furniture; OR integration systems; patient flow management solutions; patient transport solutions; sealing equipment; sterile supply management and traceability solutions; sterilizers; surgical assist systems; surgical perfusion components; loading and distribution trolleys; trays and baskets; and after sales consulting services. The company also provides automated bedding handling equipment, closure processing systems, washers, and isolation and sterile transfer products; professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in Europe, the Middle East, Africa, the Americas, Asia, and Pacific. The company has a strategic partnership with Verb Surgical Inc. to develop digital surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.

About Viewray

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Receive News & Ratings for GETINGE AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GETINGE AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.